Lantus

Despite scoring an FDA nod, Merck's biosim Lusduna must wait to challenge Lantus
Fierce Pharma
Sun, 07/23/17 - 11:40 am
FDA
Merck
biosimilars
Lusduna Nexvue
Lantus
diabetes
Sanofi
Hatch Waxman Act
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
Fri, 06/30/17 - 11:06 am
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Novo Nordisk files to add Lantus-matching CV data to Tresiba's European label
Fierce Pharma
Fri, 06/16/17 - 09:35 am
Novo Nordisk
Lantus
Tresiba
diabetes
Europe
EMA
insulin
ADA preview: 5 things to watch in diabetes
BioPharma Dive
Sun, 06/11/17 - 09:30 am
ADA
diabetes
Jardiance
Eli Lilly
Boehringer Ingelheim
Lantus
Tresiba
JNJ
Novo Nordisk
PCSK9 inhibitors
Amgen Regeneron
Sanofi
Apple
Google
insulin
Top 10 diabetes drugs by 2016 sales
Fierce Pharma
Thu, 06/8/17 - 10:04 am
diabetes
Sanofi
Novo Nordisk
Eli Lilly
Merck
Lantus
Januvia
Victoza
Levemir
Humalog
Novolog
Invokana
Sanofi enjoys solid Q1, despite continuing erosion of Lantus sales in U.S.
Fierce Pharma
Sat, 04/29/17 - 10:07 am
Sanofi
earnings
diabetes
Lantus
Sanofi May Now Have Moved Past Its Most Challenging Period, Analyst Initiates At Buy
Yahoo/Benzinga
Fri, 04/7/17 - 12:07 am
Sanofi
Lantus
Plavix
patents
Could This Look-A-Like Drug Be Merck's Next Big Seller?
Motley Fool
Sat, 10/29/16 - 01:21 pm
MK-1293
Merck
diabetes
insulin
Lantus
biosimilars
Will Sanofi See More Growth from Its Blockbuster Insulin Drug?
Market Realist
Thu, 09/15/16 - 09:33 am
Sanofi
insulin
diabetes
Lantus
Sanofi can’t even buy a break now, as rival Novo speeds ahead on diabetes showdown
Endpoints
Mon, 08/22/16 - 11:41 am
Sanofi
Novo Nordisk
diabetes
Lantus
Xultophy
Merck Results Underscore Need To Go Big Or Go Home In Diabetes Market
Forbes
Fri, 07/29/16 - 08:47 pm
Merck
diabetes
Sanofi
Januvia
Lantus
Eli Lilly Launches Lantus Biosimilar To Boost Sales, But Not Without Risks
Seeking Alpha
Tue, 06/28/16 - 05:33 pm
Eli Lilly
Lantus
biosimilars
diabetes
Basaglar
Merck eyes US approval with positive data on Lantus copy
BioPharma Dive
Tue, 06/14/16 - 09:30 pm
Merck
diabetes
Lantus
MK-1293
Sanofi
Sanofi Wins FDA Panel’s Backing for Once-Daily Diabetes Combo
Bloomberg
Wed, 05/25/16 - 09:35 pm
Sanofi
FDA
advisory panels
diabetes
lixisenatide
Lantus
FDA Staff Questions Usefulness of Sanofi’s Diabetes Drug Combo
Bloomberg
Mon, 05/23/16 - 10:16 am
FDA
Sanofi
diabetes
clinical trials
Lantus
Lyxumia
Express Scripts unimpressed by insulin data on Novo's Tresiba
BioPharma Dive
Thu, 03/3/16 - 10:41 am
Express Scripts
insulin
Novo Nordisk
diabetes
Tresiba
Lantus
Insulin wars heat up as Novo's Tresiba bests Lantus in major safety outcomes trial
BioPharma Dive
Thu, 02/4/16 - 09:27 am
Novo Nordisk
insulin
diabetes
Tresiba
Lantus
Sanofi
Sanofi takes an FDA shortcut with its diabetes combo, racing with Novo
Fierce Biotech
Wed, 12/23/15 - 09:34 pm
Sanofi
Novo Nordisk
diabetes
FDA
Lantus
lixisenatide
Lilly gets its Lantus copycat Basaglar approved by FDA—but not as a biosimilar
BioPharma Dive
Thu, 12/17/15 - 02:00 pm
diabetes
Eli Lilly
Lantus
Basaglar
insulin
FDA
biosimilars
Sanofi
FDA approves cheaper version of top-selling diabetes drug
Yahoo/Reuters
Wed, 12/16/15 - 07:56 pm
FDA
diabetes
insulin
Lantus
Eli Lilly
Boehringer Ingelheim
Sanofi

Pages